06.10.14 11:38 Dow Jones Newswires

DJ Therapy decision in breast cancer: EndoPredict(R) predicts benefit from chemotherapy - Independent research group confirms chemo benefit for high-risk patients

(DGAP-Media / 06.10.2014 / 11:37)

Patients for whom EndoPredict(R) predicts a high risk of relapse have much greater benefit from chemotherapy than low-risk patients. This is the result published by an independent research group after investigating gene expression profiles and histological data of 553 patients. All patients were suffering from hormone receptor-positive and HER2/neu-negative breast cancer.

The authors conclude that a low risk EndoPredict result is a convincing reason not to give chemotherapy to a breast cancer patient. On the other hand, a high risk result is an indicator that the patient will benefit from chemotherapy.

"EndoPredict is the first test of its kind for which exclusively hormone receptor-positive and HER2/neu-negative tumours were already used during its development", says Dr. Christoph Petry, CEO of the developer company Sividon Diagnostics. "It is therefore the first gene expression test really tailor-made for those breast cancer patients who need it. We are pleased that independent scientists have now confirmed that patients for whom EndoPredict has predicted a high metastatic risk are in fact helped more by chemotherapy."

Low-risk patients according to EndoPredict have a very good prognosis, and hardly benefit from chemotherapy. "The treatment would be an unnecessary burden for the patients", explains Petry. "High-risk patients frequently have a genuine benefit from chemotherapy, as has been shown again in the recent study."

The study results are published in the Cancer Letters and can be downloadad at http://www.cancerletters.info/article/S0304-3835(14)00513-8/abstract. Franois Bertucci, Pascal Finetti, Patrice Viens, Daniel Birnbaum, EndoPredict Predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer, Cancer Letters (2014), http://dx.doi.org/doi: 10.1016/j.canlet.2014.09.014

Sividon Diagnostics GmbH was founded in July 2010 as a management buyout from Siemens Healthcare Diagnostics Products in Cologne, Germany. The company aims to sustainably increase the quality of therapy-accompanying diagnostics in oncology. EndoPredict(R), the first diagnostic test from Sividon, has been available since 2011. The breast cancer prognostic test helps in deciding for which patient a chemotherapy is indicated Further information is available at http://www.sividon.com or http://www.endopredict.com.

End of Media Release

More:
DJ Therapy decision in breast cancer: EndoPredict(R) predicts benefit from chemotherapy - Independent research group ...

Comments are closed.